Universal Ibogaine Inc.
IBOGF
$0.065
-$0.005-7.14%
| 04/30/2024 | 01/31/2024 | 10/31/2023 | 07/31/2023 | 04/30/2023 | |
|---|---|---|---|---|---|
| Revenue | 285.05% | 288.87% | 69.02% | -9.20% | -39.56% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 285.05% | 288.87% | 69.02% | -9.20% | -39.56% |
| Cost of Revenue | 86.75% | 111.63% | 93.08% | 74.68% | 110.50% |
| Gross Profit | 328.37% | 464.14% | 10.80% | -105.31% | -150.14% |
| SG&A Expenses | -53.30% | -65.35% | -62.07% | -64.52% | -53.90% |
| Depreciation & Amortization | 14.48% | 10.17% | 4.64% | 5.25% | 14.51% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -16.44% | -33.29% | -40.51% | -49.98% | -39.41% |
| Operating Income | 74.30% | 79.87% | 66.33% | 59.19% | 39.39% |
| Income Before Tax | 75.03% | 83.08% | 75.99% | 78.44% | 25.10% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 75.03% | 83.08% | 75.99% | 78.44% | 25.10% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 75.03% | 83.08% | 75.99% | 78.44% | 25.10% |
| EBIT | 74.30% | 79.87% | 66.33% | 59.19% | 39.39% |
| EBITDA | 83.34% | 87.15% | 71.78% | 63.01% | 42.17% |
| EPS Basic | 79.42% | 82.78% | 75.79% | 79.39% | 30.17% |
| Normalized Basic EPS | 76.19% | 76.47% | 64.81% | 59.09% | 37.31% |
| EPS Diluted | 81.41% | 84.28% | 77.81% | 80.50% | 22.70% |
| Normalized Diluted EPS | 76.19% | 76.47% | 64.81% | 59.09% | 37.31% |
| Average Basic Shares Outstanding | 12.47% | 0.41% | 0.48% | 3.08% | 4.01% |
| Average Diluted Shares Outstanding | 12.47% | 0.41% | 0.48% | 3.08% | 4.01% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
